Quantum BioPharma is trading at $3.20 (+5.26%) in after-hours trading after Rodman & Renshaw initiated coverage with a Buy rating and an $8.00 price target, citing Lucid-MS potential.
- The stock closed at $3.04 on September 1, 2026.
- The analyst highlighted Lucid-MS as a potentially first-in-class treatment candidate for progressive multiple sclerosis.
- The move is notable against a weaker broader market, suggesting company-specific optimism.